PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study
Portfolio Pulse from Vandana Singh
PTC Therapeutics shared promising interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease patients. The study showed dose-dependent lowering of Huntingtin protein levels and PTC518 treatment was well tolerated with no serious adverse events.
June 21, 2023 | 6:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PTC Therapeutics' PTC518 shows promise in Phase 2 study for Huntington's disease, potentially boosting the company's stock price.
The positive interim data from the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease patients indicates that the drug candidate is showing promise. This could lead to increased investor confidence in PTC Therapeutics and potentially boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100